Identification of FUT7 hypomethylation as the blood biomarker in the prediction of early-stage lung cancer  

作　　者：Rong Qiao Feifei Di Jun Wang Yujie Wei Tian Xu Liping Dai Wanjian Gu Baohui Han Rongxi Yang 

机构地区：[1]Department of Pulmonary Medicine,Shanghai Chest Hospital,Shanghai Jiaotong University,Shanghai 200030,China [2]Nanjing TANTICA Biotechnology Co.Ltd,Nanjing,Jiangsu 210061,China [3]Department of Clinical Laboratory,Jiangsu Province Hospital of Chinese Medicine,Nanjing,Jiangsu 210029,China [4]Henan Institute of Medical and Pharmaceutical Sciences,Academy of Medical Science,Zhengzhou University,Zhengzhou,Henan 450001,China [5]Department of Epidemiology and Biostatistics,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China [6]Department of Environmental Genomics,Jiangsu Key Laboratory of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing,Jiangsu 211166,China [7]Department of Genetic Toxicology,The Key Laboratory of Modern Toxicology of Ministry of Education,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China

出　　处：《Journal of Genetics and Genomics》2023年第8期573-581,共9页遗传学报（英文版）

基　　金：supported by the Nanjing Social Supporting Department and Social Supporting Ministry of Jiangsu Province granted from 2018 to 2020,and the Nanjing TANTICA Co.Ltd(grant no.2018LC01.1).

摘　　要：Early detection of lung cancer (LC) is vital for reducing LC-related mortality. However, noninvasive diagnostic tools remain a great challenge. We aim to identify blood-based biomarkers for the early detection of LC. Here, LC-associated hypomethylation in alpha-1,3-fucosyltransferase VII (FUT7) is identified via the Illumina 850K array in a discovery study and validated by mass spectrometry in two independent casecontrol studies with blood samples from 1720 LC patients (86.8% LC at stage I, blood is collected before surgery and treatment) and 3143 healthy controls. Compared to the controls, blood-based FUT7 hypomethylation is identified in LC patients at stage I, and even in LC patients with malignant nodules ≤1 cm and in patients with adenocarcinoma in situ. Gender plays a role in the LC-associated FUT7 hypomethylation in blood, which is more significant in males than in females. We also reveal that FUT7 hypomethylation in LC could be enhanced by the advanced stage of cancer, involvement of lymph nodes, and larger tumor size. Based on a large sample size and semi-quantitative methods, our study reveals a strong association between blood-based FUT7 hypomethylation and LC, suggesting that methylation signatures in blood may be a group of potential biomarkers for detection of early-stage LC.

关 键 词：Lung cancer Early detection DNA methylation FUT7 Mass spectrometry 

分 类 号：R730.4[医药卫生—肿瘤]